临床研究Dengzhan Shengmai囊对血管认知障碍患者大脑结构和认知功能的神经保护作用
Mengyuan Li1,2,3, Dandan Wang1,4,3, Dongfeng Wei5,3
1State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Beijing, China.
Current Alzheimer research
|October 6, 2025
概括
山明 (DZSM) 囊在血管认知障碍 (VCI) 患者中显著改善了认知功能和灰质体积. 这种传统中医药可能通过大脑结构重塑提供神经保护,增强认知能力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是指老年学的学科.
背景情况:
- 血管认知障碍 (VCI) 是一种普遍存在的痴呆类型,治疗选择有限.
- 传统中医药Dengzhan Shengmian (DZSM) 囊对VCI症状缓解具有临床前景.
- 在VCI中DZSM的精确治疗机制仍然不完全理解.
研究的目的:
- 评估DZSM在VCI患者中的神经保护作用.
- 通过神经成像来研究DZSM对认知功能和大脑结构的影响.
- 提供证据支持DZSM对VCI的临床应用.
主要方法:
- 这是一项为期6个月的随机,双面膜,安慰剂对照试验,涉及100名VCI患者.
- 参与者被分配到DZSM或安慰剂 (每个n=50).
- 认知评估和神经成像数据在基线收集,并在6个月后进行比较.
主要成果:
- 与安慰剂相比,DZSM治疗导致了全球认知,情节性记忆,视觉空间能力和工作记忆的显著认知改善.
- 在DZSM组中,灰质体积在多个大脑区域增加,包括海马和前中心.
- 增加灰色物质体积与增强的全球认知和视觉空间功能正相关.
结论:
- DZSM囊有效地改善VCI患者的认知领域,特别是记忆,视觉空间和执行功能.
- 神经成像显示,DZSM促进了结构性大脑重塑,由增加的灰质体积证明.
- 这些结构变化与认知增强有关,这表明DZSM在VCI中的神经保护潜力.
更多相关视频
07:30Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
3.4K
05:12A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
Published on: November 22, 2024
1.3K
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
558
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
558
01:22Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822